4.7 Article

Efficacy and Safety of Multi-Session Transcranial Direct Current Stimulation on Social Cognition in Schizophrenia: A Study Protocol for an Open-Label, Single-Arm Trial

期刊

JOURNAL OF PERSONALIZED MEDICINE
卷 11, 期 4, 页码 -

出版社

MDPI
DOI: 10.3390/jpm11040317

关键词

neuromodulation; transcranial direct current stimulation (tDCS); schizophrenia; social cognition; superior temporal sulcus

资金

  1. Japan Society for the Promotion of Science (JSPS) KAKENHI [20K16635, 20H03610]
  2. Intramural Research Grant for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry (NCNP) [30-1, 30-8, 2-3, 3-1]
  3. AMED [0307081, 0307099]
  4. [JH 2020-B-08]
  5. Grants-in-Aid for Scientific Research [20K16635, 20H03610] Funding Source: KAKEN

向作者/读者索取更多资源

This study aims to investigate the effects of multi-session transcranial direct current stimulation on the superior temporal sulcus in improving social cognition deficits in patients with schizophrenia. The efficacy and safety will be evaluated through various measures including the Social Cognition Screening Questionnaire.
Backgrounds: Social cognition is defined as the mental operations underlying social behavior. Patients with schizophrenia elicit impairments of social cognition, which is linked to poor real-world functional outcomes. In a previous study, transcranial direct current stimulation (tDCS) improved emotional recognition, a domain of social cognition, in patients with schizophrenia. However, since social cognition was only minimally improved by tDCS when administered on frontal brain areas, investigations on the effect of tDCS on other cortical sites more directly related to social cognition are needed. Therefore, we present a study protocol to determine whether multi-session tDCS on superior temporal sulcus (STS) would improve social cognition deficits of schizophrenia. Methods: This is an open-label, single-arm trial, whose objective is to investigate the efficacy and safety of multi-session tDCS over the left STS to improve social cognition in patients with schizophrenia. The primary outcome measure will be the Social Cognition Screening Questionnaire. Neurocognition, functional capacity, and psychotic symptoms will also be evaluated by the Brief Assessment of Cognition in Schizophrenia, UCSD Performance-Based Skills Assessment-Brief, and Positive and Negative Syndrome Scale, respectively. Data will be collected at baseline, and 4 weeks after the end of intervention. If social cognition is improved in patients with schizophrenia by tDCS based on this protocol, we may plan randomized controlled trial.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据